Clinical Trial Update: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous NKT cells engineered with a GD2-targeted CAR and interleukin-15 for neuroblastoma in children; currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• GD2-specific CAR and IL-15 expressing autologous NKT cells

Snippet

Sponsor: Baylor College of Medicine | Conditions: Neuroblastoma | Phase 1 | Status: RECRUITING